Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback